Sepsis & Critical Care Management
MAST Group is excited to announce a multi-region distribution agreement with Nanōmix Corporation, a leader in the development of mobile point-of-care (POC) diagnostics, to distribute the Nanōmix eLab® system in the United Kingdom, Germany, France, Ireland and South Africa.
Continue ReadingComparative clinical performance of MAST URI® Plates and Disc Diffusion
MAST URI® Plates are made to the current EUCAST breakpoints for urinary tract infections.
Continue ReadingSepsis & Critical Care Management
MAST Group is excited to announce a multi-region distribution agreement with Nanōmix Corporation, a leader in the development of mobile point-of-care (POC) diagnostics, to distribute the Nanōmix eLab® system in the United Kingdom, Germany, France, Ireland and South Africa.
Continue ReadingWorld Antimicrobial Awareness Week: 18 - 24 November
Will you 'go blue' for World Antimicrobial Awareness Week this week?
Continue ReadingTo FIT-finity and beyond!
This is the topic Mast Group Product Specialist Emily George will be discussing at the ACB UKMedLab22 scientific meeting on Wednesday 9th November.
Continue ReadingMAST® SPUTAGEST – Available from Stock
MAST® SPUTAGEST liquefying agent permits easy and effective isolation of organisms from sputum samples.
Continue ReadingNew Approved CLSI Criteria for Bovine Mastitis Pathogens
Reliable and accurate susceptibility testing of mastitis pathogens to Kanamycin-Cefalexin 30-15µg combination is now easier for Veterinary practitioners.
Continue ReadingNew addition to the MASTDISCS® range – Ceftobiprole 5µg available now!
Mast is pleased to announce the launch of Ceftobiprole 5µg to the MASTDISCS® Antimicrobial Susceptibility Test range.
Continue ReadingMast continue to support the fight against AMR
The prevalence of antibiotic resistance amongst anaerobes is emerging and in recent decades several species have developed resistance to broad spectrum antibiotics such as Meropenem, Piperacillin-Tazobactam and Metronidazole.
Continue Reading